Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo

Isomerisation to all-trans-retinoic acid (ATRA) is widely accepted as the key mechanism underlying the favourable clinical properties of 13-cis-retinoic acid (13cisRA). As intracellular metabolism of ATRA by CYP26 may result in clinical resistance to 13cisRA, an increase in efficacy may be achieved...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, J L, Taylor, G A, Thomas, H D, Boddy, A V, Redfern, C P F, Veal, G J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359919/
https://www.ncbi.nlm.nih.gov/pubmed/17486130
http://dx.doi.org/10.1038/sj.bjc.6603779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359919/
https://www.ncbi.nlm.nih.gov/pubmed/17486130
http://dx.doi.org/10.1038/sj.bjc.6603779

Ejemplares similares